- The FDA approves Novartis' (NYSE:NVS) IL-17A inhibitor, Cosentyx (secukinumab), for the treatment of adults with active ankylosing spondylitis and active psoriatic arthritis, both life-long painful and debilitating inflammatory diseases that affect the joints and/or spine.
- The European Commission approved the two new indications in November.
- In January 2015, Cosentyx was cleared in the U.S. and EU for the treatment of adults with moderate-to-severe plaque psoriasis.
- Cosentyx is one of the company's anticipated blockbusters that is expected to generate peak sales of $1B+. Through Q3, it has posted $140M in sales.
FDA clears two new indications for Novartis' Cosentyx
This was corrected on 02/04/2019 at 10:51 PM. The two new indications were cleared in Europe in November.